Biostatisticians

15-2041.01
Median wage $105,650/yr29,030 employed (US)Rank #174 of 923 scored · top 19% by substitution

Develop and apply biostatistical theory and methods to the study of life sciences.

Sub-scores

0–100 · band = confidence interval from rater disagreement

Substitution40
Exposure40
Augmentation77

Substitution — the headline: capability discounted by cost, barriers and adoption.

Exposure — technical capability alone, regardless of whether anyone deploys it.

Augmentation — how much AI assists without replacing. High here + moderate substitution = a changing job, not a disappearing one.

Tasks on the substitution scale

25 rated tasks, binned by substitution score.

Position among all scored occupations

Distribution of 923 occupation scores; the marker is this occupation.

Tasks with substitution ≥ 70

4%

Run 1.0.0-draft.1 · computed 2026-08-05 · rater panel: claude-sonnet-5, claude-haiku-4-5-20251001 · intervals span rater disagreement.

Why this score

The five weighted dimensions of the composite, averaged across this occupation's tasks (importance-weighted, panel mean). Exact weights and formulas: /api/v1/methodology.

Task automatabilityw 35%41

panel mean rating 2.6/5 → substitution pressure 41/100

Technical feasibility todayw 20%38

panel mean rating 2.5/5 → substitution pressure 38/100

Cost vs. human wagew 15%41

panel mean rating 2.6/5 → substitution pressure 41/100

Adoption barriersw 20%inverted — strong barriers lower the score40

panel mean rating 3.4/5 (barrier strength) → substitution pressure 40/100

Sector adoption velocityw 10%40

panel mean rating 2.6/5 → substitution pressure 40/100

Task breakdown (25 tasks)

Substitution pressure per task, weighted by O*NET importance in the composite. Expand a task for the full rater audit trail — every rating, every model, every rationale.

Calculate sample size requirements for clinical studies.

79

CI 62–95 · exposure 83 · augmentation 88 · importance 4.3/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510015/5Pharmaceutical, biotech, and clinical research sectors have adopted statistical software and automated sample size calculators as standard practice for decades, with deep integration into trial design workflows and regulatory submissions.
Sector adoption velocityclaude-sonnet-53/5Pharma and clinical research sectors have moderate digitization and are increasingly adopting AI-assisted statistical tools, but regulatory conservatism slows full production-scale adoption.
Augmentation potentialclaude-haiku-4-5-202510014/5Biostatisticians use automated calculators to iterate designs, test sensitivity analyses, and visualize power curves—AI tools amplify their ability to explore parameter space and document justifications without eliminating human judgment on study design assumptions.
Augmentation potentialclaude-sonnet-55/5AI and statistical software dramatically speed up sample size calculations, allowing biostatisticians to explore multiple scenarios and assumptions efficiently while retaining oversight of design decisions.
Task automatabilityclaude-haiku-4-5-202510015/5Sample size calculation is a deterministic mathematical task with well-defined formulas (power analysis, effect size estimation). Current statistical software and AI systems can fully automate this given study parameters, meeting the ≥50% time-saving threshold with reliable output quality.
Task automatabilityclaude-sonnet-54/5Sample size calculation is a well-defined statistical procedure with established formulas and software (e.g., PASS, G*Power, R packages) that can be largely automated given correct inputs like effect size, power, and variance assumptions.,
Adoption barriersclaude-haiku-4-5-202510012/5While regulatory agencies (FDA) require sound statistical justification in clinical protocols, the calculation itself is not legally restricted to human performance; many organizations use automated tools without mandatory human sign-off on the arithmetic. Organizational practice and QA oversight provide modest friction but not legal barriers.
Adoption barriersclaude-sonnet-53/5Clinical trial sample size determinations often require sign-off by a qualified biostatistician for regulatory submissions (e.g., FDA, IRB), creating moderate accountability and liability barriers.
Cost vs. human wageclaude-haiku-4-5-202510015/5Automated sample size calculators cost pennies per study (software licensing amortized across many calculations), versus a biostatistician billable hour at $100–300+. The cost differential is at least an order of magnitude in favor of automation.
Cost vs. human wageclaude-sonnet-54/5Once inputs are defined, AI/software computation is near-instantaneous and costs a fraction of a biostatistician's billable time, though expert input and validation remain necessary.
Technical feasibility todayclaude-haiku-4-5-202510015/5Mature statistical packages (R, SAS, Python libraries) and specialized clinical trial design software have long deployed sample size calculators reliably in production. These tools are standard in pharmaceutical and research organizations and perform the calculations correctly when inputs are specified.
Technical feasibility todayclaude-sonnet-53/5Statistical software and AI-assisted tools can compute sample sizes reliably, but selecting appropriate assumptions, study design nuances, and regulatory justification still require expert review, so full automation in production is only partial.

Prepare tables and graphs to present clinical data or results.

69

CI 59–79 · exposure 70 · augmentation 100 · importance 4.3/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510014/5Biostatistics, clinical research, and pharmaceutical sectors are high-digitization, information-intensive domains with rapid AI tool adoption. Major CROs, pharmaceutical companies, and academic medical centers actively deploy automated visualization pipelines and AI-assisted analytics, reflecting faster-than-average adoption in professional services.
Sector adoption velocityclaude-sonnet-53/5Pharma and clinical research sectors are adopting AI/automation for statistical programming and reporting, but adoption is more cautious than in tech or finance due to regulatory validation requirements, so uptake is moderate and pilot-heavy.
Augmentation potentialclaude-haiku-4-5-202510015/5AI dramatically augments biostatistician productivity by automating routine graph generation, enabling rapid iteration and exploration of alternative visualizations. This allows biostatisticians to focus on statistical design and interpretation while AI handles the mechanical data-to-visual transformation, substantially raising output per analyst hour.
Augmentation potentialclaude-sonnet-55/5AI tools substantially speed up drafting of tables, listings, and graphs, letting biostatisticians focus on interpretation and QC rather than manual formatting, making this a strong augmentation use case.
Task automatabilityclaude-haiku-4-5-202510014/5AI can now automatically generate tables and graphs from clinical datasets using established data visualization libraries and large language models that interpret statistical outputs. The task is largely routine data transformation with well-defined inputs and outputs, though quality review and customization for publication standards may require human oversight to ensure medical accuracy and regulatory compliance.
Task automatabilityclaude-sonnet-54/5Generating tables and graphs from clinical datasets is a well-structured task that current AI coding assistants and data tools (e.g., R/Python code generation, automated report tools) can largely perform given clean data and clear specifications, saving significant time on formatting and boilerplate.
Adoption barriersclaude-haiku-4-5-202510012/5Few hard regulatory or legal barriers prevent automation of table/graph generation itself, though clinical trials and regulatory submissions (FDA, EMA) require human statistical expertise and sign-off on interpretation. The task is purely technical output formatting with no inherent licensing requirement, though organizational quality-control norms may slow adoption.
Adoption barriersclaude-sonnet-53/5While no license is legally required to make a chart, clinical trial deliverables are subject to regulatory scrutiny (FDA submissions) and require sign-off by qualified statisticians, creating moderate compliance-driven friction.
Cost vs. human wageclaude-haiku-4-5-202510015/5AI-driven automation via cloud-based tools or open-source libraries costs a fraction of biostatistician labor per visualization produced. Loaded biostatistician wages ($50–150k+ annually) far exceed the inference and integration costs of current systems, yielding at least an order-of-magnitude cost advantage.
Cost vs. human wageclaude-sonnet-53/5AI can cut drafting time substantially, but the need for statistical validation, regulatory compliance (e.g., CDISC standards), and QC review by trained biostatisticians keeps oversight costs meaningful relative to savings.
Technical feasibility todayclaude-haiku-4-5-202510014/5Multiple deployed products (Python/R libraries, Tableau, Power BI, specialized clinical analytics platforms, and AI coding assistants) reliably produce publication-ready tables and graphs from structured clinical data. Some integration friction and formatting adjustments remain, but production systems demonstrably perform this task at scale in academic and pharmaceutical settings.
Technical feasibility todayclaude-sonnet-53/5Products like ChatGPT with code interpreter, RStudio/AI plugins, and pharma-specific automated reporting tools (e.g., TFL generation software) exist and are used, but clinical trial tables often require validated, regulatory-compliant outputs still checked and adjusted by biostatisticians.

Design or maintain databases of biological data.

59

CI 35–84 · exposure 58 · augmentation 88 · importance 3.7/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510014/5Biotech, pharma, and healthcare IT sectors are adopting AI-assisted development tools (Copilot, Claude) rapidly; major academic medical centers and CROs are piloting AI-driven data infrastructure. Adoption in this information-intensive domain is fast and measurable in production systems.
Sector adoption velocityclaude-sonnet-52/5Biostatistics and life sciences research are moderate adopters of AI tools for coding assistance, but full database design/maintenance automation is not yet a common production pattern in this specialized domain.
Augmentation potentialclaude-haiku-4-5-202510015/5AI tools dramatically augment biostatistician productivity by auto-generating boilerplate schemas, suggesting optimizations, and automating repetitive maintenance tasks, freeing domain experts for validation, integration strategy, and scientific oversight. This is a canonical augmentation use case in professional services.
Augmentation potentialclaude-sonnet-54/5AI coding assistants substantially speed up schema drafting, query writing, documentation, and debugging for database maintenance tasks, meaningfully boosting biostatistician productivity while they retain design authority.
Task automatabilityclaude-haiku-4-5-202510015/5Database design and maintenance for biological data involves schema creation, data ingestion, validation, and query optimization—all routine tasks where modern AI tools (LLMs, code-generating agents) can handle structural design, code generation, and deployment with >50% time savings at equal quality. Biostatisticians currently spend substantial time on boilerplate work that AI can fully automate.
Task automatabilityclaude-sonnet-52/5Database design requires understanding of research context, data relationships, and downstream analytical needs that current AI cannot fully infer without significant human specification; AI can generate schema code but not make the underlying design decisions autonomously.4/10 time saving realistic at best for full task.5,
Adoption barriersclaude-haiku-4-5-202510012/5Few regulatory or legal barriers exist to automating database design and maintenance itself, though data governance, HIPAA compliance, and institutional review may impose human oversight requirements. Most barriers are organizational inertia and risk-aversion rather than hard legal mandates.
Adoption barriersclaude-sonnet-52/5No licensing requirement specifically governs database design, but data integrity, regulatory compliance (e.g., clinical trial data standards), and institutional data governance policies create moderate friction against full automation.
Cost vs. human wageclaude-haiku-4-5-202510014/5API-based AI inference (LLM queries) costs pennies to dollars per task, while biostatistician labor (fully loaded ~$120–150k/year) costs $60–100+ per hour. Amortized inference and integration costs are 1–2 orders of magnitude cheaper than manual database design and maintenance work.
Cost vs. human wageclaude-sonnet-52/5While AI coding assistance reduces some drafting time cheaply, the ongoing maintenance, validation against biological standards, and error-checking still require costly expert biostatistician time, keeping overall cost comparable to human-only workflows.
Technical feasibility todayclaude-haiku-4-5-202510014/5Deployed products like GitHub Copilot, ChatGPT-4, and specialized code-generation tools are demonstrably used in production to design database schemas, write SQL, and generate ETL pipelines at scale. AI-assisted or end-to-end database maintenance is widely deployed in industry, though complex edge cases and domain-specific regulatory requirements may still require human review.
Technical feasibility todayclaude-sonnet-52/5Products like GitHub Copilot or database design assistants can help draft schemas or SQL, but no deployed product autonomously designs and maintains biological databases in production without expert oversight.

Write program code to analyze data with statistical analysis software.

56

CI 50–62 · exposure 58 · augmentation 88 · importance 4.3/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510013/5AI-assisted coding is increasingly common in biotech and pharma (pilots and some production use), but adoption remains uneven; many teams still rely on human experts to design and validate statistical code rather than deploying AI end-to-end.
Sector adoption velocityclaude-sonnet-53/5Pharma/biotech and clinical research are moderately digitized but conservative and heavily regulated, so AI coding tool adoption is growing but validation and compliance concerns slow full production deployment.
Augmentation potentialclaude-haiku-4-5-202510014/5AI code generation significantly accelerates routine coding tasks, boilerplate generation, and exploratory analysis, allowing biostatisticians to focus on study design and interpretation rather than syntax. This is a strong augmentation use case even if full automation is not yet reliable.
Augmentation potentialclaude-sonnet-55/5AI code generation and debugging assistance is already a major productivity booster for statistical programmers, drafting boilerplate code, suggesting functions, and catching syntax errors while the biostatistician retains oversight of methodology and validation.
Task automatabilityclaude-haiku-4-5-202510013/5Current AI can generate boilerplate statistical code and handle routine data wrangling, but struggle with complex study designs, novel statistical questions, or debugging domain-specific logic. A biostatistician typically needs human judgment on analysis approach and validation, limiting end-to-end automation below the 50% time-saving threshold for non-standard analyses.
Task automatabilityclaude-sonnet-54/5Current LLM-based coding assistants (Copilot, Claude, GPT-4 class models) can generate R/SAS/Python statistical analysis code from natural-language specifications with substantial time savings, though complex trial designs and edge-case validation still need expert review.
Adoption barriersclaude-haiku-4-5-202510013/5Regulatory environments (FDA, EMA) often require documented statistical analysis plans and human sign-off, creating friction, though the writing of code itself is not legally restricted. Organizations also prefer human accountability for analysis decisions.
Adoption barriersclaude-sonnet-53/5No licensing requirement to write code itself, but regulatory submissions (e.g., FDA) require validated, human-verified statistical programming with audit trails, creating moderate institutional friction.
Cost vs. human wageclaude-haiku-4-5-202510013/5AI inference and integration costs for code generation are now modest (pennies per session), but a full replacement analysis still requires human oversight and validation, keeping total cost per reliable output roughly comparable to junior biostatistician labor.
Cost vs. human wageclaude-sonnet-54/5AI coding assistance costs a small fraction of a biostatistician's hourly wage, and even with required human review the net cost per unit of code output is markedly lower.
Technical feasibility todayclaude-haiku-4-5-202510013/5Products like GitHub Copilot and Claude can write working R, Python, and SAS code with reasonable reliability for standard tasks, but error rates remain material on edge cases and domain expertise is often needed to catch logical flaws in statistical workflows.
Technical feasibility todayclaude-sonnet-53/5AI coding assistants are deployed widely in production for general code generation and are used by biostatisticians, but reliability for domain-specific statistical programming (e.g., regulatory-grade SAS macros, CDISC compliance) still requires significant human correction.

Design research studies in collaboration with physicians, life scientists, or other professionals.

54

CI 28–80 · exposure 58 · augmentation 88 · importance 4.3/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510013/5Biotech, pharma, and academic research sectors are pilot-testing AI for protocol generation, but widespread production adoption remains nascent. Most organizations still require human-led design with AI as assistive tool rather than replacement.
Sector adoption velocityclaude-sonnet-53/5Life sciences and pharma are adopting AI tools for analysis and drafting at a moderate pace, but core study design work remains largely human-led with pilots rather than full production deployment.
Augmentation potentialclaude-haiku-4-5-202510015/5AI dramatically augments biostatistician productivity by drafting protocols, suggesting alternatives, and automating literature synthesis for study design. The human biostatistician retains oversight and judgment while AI handles heavy lifting, making this a high-augmentation scenario.
Augmentation potentialclaude-sonnet-54/5AI can meaningfully assist by generating draft protocols, simulating power analyses, summarizing literature, and suggesting statistical methods, boosting biostatistician productivity while humans retain design authority.
Task automatabilityclaude-haiku-4-5-202510015/5AI can now generate full research protocols, suggest statistical designs, identify confounders, and optimize sample sizes autonomously. Modern language models can synthesize study design frameworks collaboratively with minimal human iteration, meeting the ≥50% time-saving threshold at equal or better quality.
Task automatabilityclaude-sonnet-52/5Study design requires deep scientific judgment, domain expertise, and iterative collaborative negotiation with stakeholders that current AI cannot autonomously replicate end-to-end, though it can assist with drafting protocols or power calculations.'
Adoption barriersclaude-haiku-4-5-202510013/5IRB requirements and professional liability for study design create moderate friction. Institutions typically require a licensed or credentialed biostatistician to review and take responsibility for designs, even if AI drafted them, limiting full substitution.
Adoption barriersclaude-sonnet-54/5Research designs often require sign-off from qualified statisticians/IRBs and regulatory bodies (e.g., FDA, ethics boards), creating strong institutional and legal barriers to full automation.
Cost vs. human wageclaude-haiku-4-5-202510015/5AI inference cost for generating a study protocol is a few dollars, versus a biostatistician's billable rate of $150–300/hour for protocol design work. AI is orders of magnitude cheaper per design task produced.
Cost vs. human wageclaude-sonnet-52/5Because human collaboration, judgment, and iterative negotiation are essential, AI cannot substitute the bulk of the labor, so cost savings are limited to partial drafting support rather than full task replacement.
Technical feasibility todayclaude-haiku-4-5-202510014/5Several products (Claude, GPT-4, specialized biostat tools) demonstrate reliable study design assistance in production environments. However, final regulatory and institutional review board (IRB) approval still requires human biostatistician sign-off, preventing fully autonomous end-to-end deployment.
Technical feasibility todayclaude-sonnet-52/5AI tools can help draft statistical analysis plans or suggest sample sizes, but no deployed product independently designs research studies collaboratively with domain experts at production reliability.

Analyze archival data, such as birth, death, and disease records.

52

CI 50–55 · exposure 50 · augmentation 75 · importance 3.4/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510013/5Academic medical centers and public health agencies have adopted automated and semi-automated pipelines for archival record analysis, but adoption remains uneven; many smaller institutions and legacy systems still rely heavily on manual biostatistician work.
Sector adoption velocityclaude-sonnet-53/5Biostatistics and public health research have growing but uneven AI tool adoption; some labs use AI-assisted coding and analysis pipelines, while much of the field still relies on traditional statistical software and manual validation.
Augmentation potentialclaude-haiku-4-5-202510014/5AI tools substantially augment biostatistician productivity by automating data preparation, exploratory analysis, and routine statistical testing, while domain experts focus on hypothesis formulation, validation, and interpretation of results.
Augmentation potentialclaude-sonnet-54/5AI significantly assists with data cleaning, exploratory analysis, code generation for statistical models, and drafting interpretations, substantially speeding up the workflow while the biostatistician retains final analytical judgment.
Task automatabilityclaude-haiku-4-5-202510013/5AI can automate significant portions of archival data analysis—data cleaning, standardization, and basic statistical computation—but typically requires substantial domain expertise and human judgment to handle heterogeneous data formats, missing values, and interpretation of historical records. Achieving >50% time savings with equal quality depends heavily on data quality and task specificity.
Task automatabilityclaude-sonnet-53/5AI can automate substantial portions of data cleaning, statistical modeling, and summary generation from archival records, but complex epidemiological interpretation, data quality judgment calls, and study design still require human expertise.
Adoption barriersclaude-haiku-4-5-202510012/5While no licensing requirement mandates human review for data analysis itself, institutional review boards, data governance policies, and liability concerns around statistical conclusions on health records create moderate friction. Patient privacy regulations (HIPAA, GDPR) also impose compliance overhead but do not legally require human sign-off.
Adoption barriersclaude-sonnet-53/5No licensing requirement mandates a human biostatistician sign off on all analyses, but publication, regulatory submissions (e.g., FDA), and epidemiological reporting often require credentialed oversight and methodological accountability.
Cost vs. human wageclaude-haiku-4-5-202510013/5AI-driven data processing and statistical analysis tools are cost-competitive with biostatistician labor for structured, repeatable analysis, but integration, validation, and human oversight for archival work add overhead that often keeps total cost comparable to traditional labor.
Cost vs. human wageclaude-sonnet-53/5AI tools can reduce time spent on routine data wrangling and exploratory analysis, but the need for skilled statisticians to validate methodology and interpret results for regulatory/scientific purposes keeps overall costs only moderately lower.
Technical feasibility todayclaude-haiku-4-5-202510013/5Deployed products (statistical software with ML, data pipeline automation tools) can handle structured archival data analysis, but real-world performance degrades with poorly digitized, inconsistently formatted, or sparse historical records. Production use exists but with material limitations in generalization across different archive types.
Technical feasibility todayclaude-sonnet-53/5Statistical software with AI-assisted features and code-generation tools (e.g., for R/Python/SAS pipelines) are used in production, but fully autonomous, reliable analysis of messy archival health records without expert oversight is not yet standard practice.

Read current literature, attend meetings or conferences, and talk with colleagues to keep abreast of methodological or conceptual developments in fields such as biostatistics, pharmacology, life sciences, and social sciences.

49

CI 37–60 · exposure 42 · augmentation 88 · importance 4.3/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510013/5Academic and pharmaceutical organizations increasingly use AI-powered literature tools and aggregators, but adoption remains patchy; many biostatisticians still rely on manual conference attendance and peer discussion, with full automation lagging.
Sector adoption velocityclaude-sonnet-53/5Life sciences and biostatistics fields are adopting AI-based literature tools moderately fast, though academic and pharma research settings tend to be more conservative than pure information/software sectors.
Augmentation potentialclaude-haiku-4-5-202510014/5AI excels at surfacing relevant papers, generating summaries of conference abstracts, and flagging methodological trends, substantially augmenting a biostatistician's ability to consume and filter large volumes of information while the human focuses on critical evaluation and application.
Augmentation potentialclaude-sonnet-55/5AI dramatically accelerates literature discovery, summarization, and trend-spotting, letting biostatisticians cover far more material while still attending meetings and engaging with colleagues themselves.
Task automatabilityclaude-haiku-4-5-202510012/5While AI can summarize papers and scan conference materials, staying 'abreast of developments' requires synthesizing evolving methodological advances, contextualizing them within a biostatistician's specific work, and understanding nuance—tasks that still depend heavily on human judgment and domain expertise to filter signal from noise.
Task automatabilityclaude-sonnet-53/5AI can summarize literature and surface relevant papers efficiently, cutting reading time substantially, but attending conferences and networking with colleagues for tacit knowledge exchange cannot be automated.
Adoption barriersclaude-haiku-4-5-202510013/5Professional standards and organizational culture expect biostatisticians to maintain direct awareness and collegial engagement; no hard licensing barrier prevents AI assistance, but professional norms and the need for human judgment on methodological validity create meaningful friction.
Adoption barriersclaude-sonnet-51/5No licensing or regulatory requirement mandates human-only literature review or professional development; it's an informal, self-directed task with no legal barrier to AI assistance.
Cost vs. human wageclaude-haiku-4-5-202510012/5AI literature review and conference monitoring tools are moderately priced, but the loaded wage for a biostatistician's time spent on professional development is high; cost parity is approximate, and the human remains essential for synthesis and judgment.
Cost vs. human wageclaude-sonnet-53/5AI literature review tools are cheap relative to a biostatistician's time for the reading component, but the full task includes conference travel and networking that AI cannot substitute, keeping overall cost savings moderate.
Technical feasibility todayclaude-haiku-4-5-202510013/5AI tools (literature aggregators, conference summarizers, citation analysis) exist and work but cannot fully replace the human tasks of attending meetings, engaging in collegial dialogue, and evaluating methodological fit; these products assist but require human participation and interpretation.
Technical feasibility todayclaude-sonnet-53/5Products like literature summarization tools, research assistants, and AI search engines (e.g., Elicit, Consensus, Perplexity) are deployed and used by researchers today, though they still require human verification and cannot replace conference attendance or peer discussion.

Develop or implement data analysis algorithms.

43

CI 25–61 · exposure 38 · augmentation 88 · importance 4.2/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510014/5Biotech, pharma, and clinical research organizations are rapidly adopting AI coding assistants and algorithm-drafting tools as part of standard workflows; adoption is particularly fast in pre-clinical and analysis phases.
Sector adoption velocityclaude-sonnet-52/5Pharma and clinical research sectors are cautious adopters of AI for core statistical methodology due to regulatory scrutiny and validation requirements, with pilots more common than production deployment.
Augmentation potentialclaude-haiku-4-5-202510015/5AI-powered code generation and algorithm suggestion substantially boost biostatistician productivity by accelerating prototyping, testing, and implementation, allowing humans to focus on problem framing, validation, and biological interpretation.
Augmentation potentialclaude-sonnet-54/5AI coding assistants and tools like Copilot substantially speed up implementation of standard algorithms (e.g., in R/SAS/Python), letting biostatisticians focus on design and validation while automating routine coding.
Task automatabilityclaude-haiku-4-5-202510013/5AI can assist in algorithm selection, code generation, and parameter tuning using tools like GPT-4 and specialized libraries, but developing novel statistical algorithms requires domain expertise, validation, and domain-specific reasoning that AI currently cannot reliably execute end-to-end without significant human oversight and iteration.
Task automatabilityclaude-sonnet-52/5Developing novel statistical/computational algorithms for biostatistical analysis requires deep domain expertise, methodological innovation, and validation against complex biological/clinical constraints that current AI cannot reliably do end-to-end without heavy human oversight.
Adoption barriersclaude-haiku-4-5-202510012/5While regulatory frameworks (FDA, EMA) scrutinize implemented algorithms in clinical contexts, the development phase itself has few legal barriers preventing AI tool use; however, organizational risk-aversion and validation standards create moderate friction.
Adoption barriersclaude-sonnet-54/5Biostatistical work supporting clinical trials and regulatory submissions (e.g., FDA) requires credentialed statisticians to develop and sign off on methods, creating strong liability and regulatory barriers to full automation.
Cost vs. human wageclaude-haiku-4-5-202510014/5The inference cost of AI-assisted algorithm development is substantially lower than the loaded salary of a biostatistician (~$120k+), especially when amortized across multiple projects, though integration and validation overhead partially offset this advantage.
Cost vs. human wageclaude-sonnet-52/5While AI can cheaply produce code snippets, the human cost of validating, debugging, and ensuring statistical/regulatory correctness for clinical data remains high, keeping all-in cost comparable to or only modestly less than human effort.
Technical feasibility todayclaude-haiku-4-5-202510013/5Deployed products (GitHub Copilot, Claude, ChatGPT) can generate functional statistical code and suggest algorithms for well-defined problems, but they frequently produce implementation errors, miss edge cases, and struggle with rigorous validation requirements essential in biostatistics production environments.
Technical feasibility todayclaude-sonnet-52/5AI coding assistants can generate boilerplate statistical code or suggest standard methods, but no deployed product reliably designs or validates novel data analysis algorithms for biostatistics in production settings.

Plan or direct research studies related to life sciences.

42

CI 11–74 · exposure 41 · augmentation 88 · importance 4.0/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510014/5Biotech, pharma, and academic biostatistics units are rapidly piloting AI for protocol drafting and exploratory analysis; major contract research organizations are integrating LLM-assisted planning into workflows.
Sector adoption velocityclaude-sonnet-52/5Life sciences/biostatistics research organizations are adopting AI for data analysis and drafting but overall strategic study leadership remains largely untouched by automation.
Augmentation potentialclaude-haiku-4-5-202510015/5AI dramatically augments biostatistician productivity by rapidly generating candidate designs, literature syntheses, and statistical frameworks that the human then refines and validates, enabling focus on high-judgment aspects of study design.
Augmentation potentialclaude-sonnet-54/5AI can meaningfully assist with literature synthesis, protocol drafting, statistical design suggestions, and study timeline planning, augmenting the biostatistician's productivity while they retain decision-making authority.
Task automatabilityclaude-haiku-4-5-202510015/5AI systems can draft study protocols, design statistical analyses, identify optimal trial architectures, and generate comprehensive research plans based on literature and best practices, achieving substantial time savings while maintaining quality comparable to human biostatisticians on routine studies.
Task automatabilityclaude-sonnet-51/5Planning and directing research studies requires original scientific judgment, hypothesis formation, resource allocation, and stakeholder coordination that current AI cannot autonomously execute end-to-end.
Adoption barriersclaude-haiku-4-5-202510013/5While no strict legal licensing requirement exists for study planning itself, regulatory frameworks (FDA, IRB) and liability concerns for downstream research quality create organizational friction; clients often prefer human sign-off on critical decisions.
Adoption barriersclaude-sonnet-54/5Research studies in life sciences are subject to IRB oversight, regulatory compliance (FDA/GCP), and require accountable human leadership with domain expertise and legal responsibility.
Cost vs. human wageclaude-haiku-4-5-202510014/5LLM-based research planning and analysis is extremely cheap (~dollars per study outline) compared to the loaded cost of a biostatistician ($120–180k annually), making the ratio highly favorable even accounting for human oversight.
Cost vs. human wageclaude-sonnet-52/5Because AI cannot perform the directing/leadership role itself, any cost comparison is for partial support tasks only, so overall the human-led process remains the dominant cost driver.
Technical feasibility todayclaude-haiku-4-5-202510013/5Deployed AI writing assistants and statistical software can generate competent study plans and analyses, but current systems struggle with novelty, regulatory compliance edge cases, and domain-specific judgment; human review remains necessary in production biostatistics environments.
Technical feasibility todayclaude-sonnet-51/5No deployed product independently plans or directs biostatistical research studies; existing tools only assist with sub-components like literature review or protocol drafting.

Write research proposals or grant applications for submission to external bodies.

42

CI 35–50 · exposure 42 · augmentation 75 · importance 3.8/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Biostatisticians and research institutions have begun using LLMs for drafting assistance, but adoption remains in the pilot and augmentation phase; few organizations report systematic replacement of grant-writing labor, and risk-averse institutions prefer human-led processes.
Sector adoption velocityclaude-sonnet-53/5Academic and research institutions show growing but uneven adoption of AI writing tools for grants, with many funders and universities still developing policies, indicating moderate rather than fast deep adoption.
Augmentation potentialclaude-haiku-4-5-202510014/5AI excels at accelerating proposal drafting, literature synthesis, and generating multiple framing options for review. Biostatisticians using LLMs for initial outlines and iterative revision report substantial productivity gains while retaining full control over scientific strategy and credibility.
Augmentation potentialclaude-sonnet-54/5AI substantially speeds up drafting, editing, literature summarization, and formatting of research proposals, meaningfully boosting biostatistician productivity while they retain control over technical content and final decisions.
Task automatabilityclaude-haiku-4-5-202510012/5AI can draft proposal sections (literature reviews, methods outlines) but cannot independently generate the novel research ideas, specific funding strategy, or institution-specific customization required for competitive grants. Human expertise in positioning and risk mitigation remains essential.
Task automatabilityclaude-sonnet-53/5AI can draft significant portions of grant text (background, methods framing, literature synthesis) but still requires substantial human input on novel study design, statistical planning, and institution-specific requirements, limiting time savings below full end-to-end automation.
Adoption barriersclaude-haiku-4-5-202510013/5Grant review agencies and institutional review boards expect human accountability, and funding bodies often require signatures by qualified personnel. Organizational norms also favor human authorship of research vision, creating friction against full automation.
Adoption barriersclaude-sonnet-53/5No formal licensing requirement mandates a human write the proposal, but institutional review, PI sign-off, and funder scrutiny of methodological rigor create meaningful friction against pure AI authorship.
Cost vs. human wageclaude-haiku-4-5-202510012/5AI drafting and editing tools reduce time on boilerplate sections, but grants require deep domain knowledge and strategy—the loaded cost of human biostatistician oversight, revision, and intellectual content generation remains substantially higher than the AI inference cost.
Cost vs. human wageclaude-sonnet-53/5AI drafting tools are cheap per word generated, but the overall cost of producing a fundable, technically sound proposal still requires substantial expert biostatistician time for review and correction, keeping total cost roughly comparable to human-only effort in many cases.
Technical feasibility todayclaude-haiku-4-5-202510013/5LLMs can produce proposal text and structure templates exist in production, but no deployed system reliably handles the full end-to-end proposal workflow including funder-specific compliance, statistical rigor validation, and strategic framing without material human revision.
Technical feasibility todayclaude-sonnet-53/5LLM-based writing assistants are widely used to draft and edit grant proposals today, but accuracy on statistical methodology, budget justification, and compliance with funder-specific formats still requires heavy human review.

Prepare statistical data for inclusion in reports to data monitoring committees, federal regulatory agencies, managers, or clients.

41

CI 41–41 · exposure 50 · augmentation 75 · importance 4.2/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510013/5Biostatistics teams in pharma and academia are actively piloting automated data pipelines and AI-assisted analysis, but production deployment remains selective and cautious because regulatory risk is high. Adoption is faster in lower-stakes internal reporting than in submissions to federal agencies.
Sector adoption velocityclaude-sonnet-53/5Pharma and clinical research organizations are piloting AI-assisted reporting and automation tools, but adoption in regulated, high-stakes reporting contexts remains cautious and slower than in general professional services.
Augmentation potentialclaude-haiku-4-5-202510014/5Current AI systems are highly effective at assisting biostatisticians with data cleaning, variable coding, formatting templates, and exploratory summaries—genuinely raising productivity while the human maintains oversight and judgment on regulatory correctness and statistical interpretation.
Augmentation potentialclaude-sonnet-54/5AI tools substantially speed up drafting, formatting, and summarizing statistical outputs for reports, letting biostatisticians focus on interpretation, validation, and regulatory nuance.
Task automatabilityclaude-haiku-4-5-202510013/5AI can automate substantial portions of data preparation—cleaning, formatting, and routine statistical summarization—but the task requires domain judgment about which data to include, how to present findings accurately for regulatory contexts, and validation of statistical correctness. Reaching 50% time savings is feasible with current systems, but full end-to-end automation without biostatistician review is not yet reliable.
Task automatabilityclaude-sonnet-53/5AI can automate much of the data summarization, table/figure generation, and drafting of statistical sections, but final report preparation requires domain-specific judgment, regulatory compliance checks, and validation that current systems cannot fully replace end-to-end.
Adoption barriersclaude-haiku-4-5-202510014/5Regulatory contexts (FDA submissions, clinical trial data monitoring) impose strict requirements for accuracy, traceability, and sign-off by qualified personnel. Liability for statistical errors in regulatory submissions creates asymmetric risk, and many jurisdictions require a licensed biostatistician to validate and certify final submissions.
Adoption barriersclaude-sonnet-54/5Regulatory submissions (e.g., FDA, data monitoring committees) require qualified biostatisticians to sign off and take responsibility for statistical accuracy and interpretation, creating strong professional and liability-driven barriers.
Cost vs. human wageclaude-haiku-4-5-202510012/5The biostatistician wage is typically $70k–$100k+ loaded annually. AI tools (cloud compute, LLMs, automation) cost hundreds to thousands per month but require significant integration overhead and human supervision. The all-in cost of AI-assisted preparation is currently comparable to or slightly higher than a junior biostatistician, not cheaper.
Cost vs. human wageclaude-sonnet-52/5While AI can cut drafting time, the need for statistician oversight, validation against regulatory standards, and compliance documentation keeps costs closer to comparable rather than order-of-magnitude cheaper.
Technical feasibility todayclaude-haiku-4-5-202510013/5Products for statistical analysis and data transformation (Python/R automation, cloud analytics platforms) exist and are used in production, but tailored preparation for regulatory or committee contexts still requires human oversight and customization. Material error rates remain in sensitivity analyses, data subsetting, and compliance-critical formatting.
Technical feasibility todayclaude-sonnet-53/5Statistical software and AI-assisted reporting tools (e.g., automated table generation, R Markdown/Shiny-based pipelines) are deployed in pharma and clinical settings, but full autonomous preparation of regulatory-ready reports still requires substantial human review and scope is narrow.

Monitor clinical trials or experiments to ensure adherence to established procedures or to verify the quality of data collected.

38

CI 25–51 · exposure 38 · augmentation 88 · importance 3.9/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510014/5Clinical research and pharmaceutical sectors are highly digitized, well-funded, and face strong regulatory compliance pressures that drive adoption of monitoring automation. Major CROs and pharma companies have deployed AI-assisted monitoring systems at scale, with measurable displacement of manual monitoring labor.
Sector adoption velocityclaude-sonnet-52/5Pharma and clinical research sectors are historically slow adopters of full automation due to regulatory scrutiny, though risk-based monitoring and centralized statistical monitoring tools are gradually being adopted in pilot and production forms.
Augmentation potentialclaude-haiku-4-5-202510015/5AI monitoring tools substantially augment biostatistician productivity by automating routine surveillance, highlighting anomalies in real time, and freeing expert time for interpretation and judgment. This is a canonical case of augmentation where humans remain in the loop while their analytic capacity expands.
Augmentation potentialclaude-sonnet-54/5AI-driven statistical monitoring tools significantly enhance a biostatistician's ability to detect anomalies, flag sites for review, and process large volumes of trial data faster, while humans retain decision-making authority.
Task automatabilityclaude-haiku-4-5-202510013/5AI can automate significant portions of data quality checks, flagging anomalies, missing values, and protocol deviations through pattern recognition and rule-based systems. However, complex judgment calls about the clinical significance of deviations or contextual assessment of data integrity typically require human biostatistician oversight, limiting full end-to-end automation.
Task automatabilityclaude-sonnet-52/5AI can flag data anomalies and check some protocol deviations, but comprehensive trial monitoring requires site visits, judgment about clinical context, and regulatory accountability that current systems cannot fully replace.ed
Adoption barriersclaude-haiku-4-5-202510014/5Regulatory frameworks (FDA, ICH guidelines) place explicit responsibility on qualified biostatisticians to ensure data integrity and protocol compliance in clinical trials, creating strong legal and professional accountability barriers. Automated systems may flag issues, but a licensed biostatistician must typically validate findings and sign off.
Adoption barriersclaude-sonnet-54/5Clinical trial monitoring is governed by GCP regulations and FDA/EMA requirements that mandate qualified personnel sign off on data integrity and protocol adherence, creating strong regulatory and liability barriers.
Cost vs. human wageclaude-haiku-4-5-202510014/5Automated monitoring systems are far cheaper to deploy per trial than employing additional biostatisticians for continuous surveillance, though setup and maintenance costs are non-trivial. Once integrated, the per-task cost of automated checks is orders of magnitude lower than manual review.
Cost vs. human wageclaude-sonnet-52/5AI tools can cheaply flag outliers or inconsistent data patterns, but the overall monitoring process still requires substantial human oversight, site coordination, and judgment, keeping total cost comparable to human-led processes.
Technical feasibility todayclaude-haiku-4-5-202510013/5Commercial data quality and clinical trial management platforms with built-in anomaly detection exist and are deployed in practice, but they function as monitoring aids rather than fully autonomous systems. Material error rates in edge cases and the need for human verification of flagged issues mean these tools operate at production scale but with clear human-in-the-loop requirements.
Technical feasibility todayclaude-sonnet-52/5Deployed products exist for statistical anomaly detection and risk-based monitoring dashboards, but end-to-end trial monitoring including data quality verification still relies heavily on human CRAs and biostatisticians in production settings.

Prepare articles for publication or presentation at professional conferences.

37

CI 25–50 · exposure 38 · augmentation 63 · importance 4.0/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Biostatisticians work in regulated research environments (pharmaceuticals, academic medicine) with high publication standards and skepticism toward automation of scientific writing. Adoption of AI for full article production remains limited; use is mostly supplementary for grammar and style.
Sector adoption velocityclaude-sonnet-53/5Academic and pharma/biostatistics sectors show moderate AI adoption for writing assistance, with growing but cautious use due to publication ethics concerns and disclosure requirements.
Augmentation potentialclaude-haiku-4-5-202510013/5AI can usefully assist with drafting background sections, polishing prose, formatting references, and generating figure captions, raising productivity on lower-stakes writing components while the biostatistician retains full control over statistical framing and claims.
Augmentation potentialclaude-sonnet-54/5AI substantially speeds up drafting, literature summarization, editing, and slide creation, letting biostatisticians focus more time on interpretation and validation of results.
Task automatabilityclaude-haiku-4-5-202510012/5AI can draft article sections and improve language, but cannot end-to-end produce publication-ready manuscripts meeting journal standards without substantial human oversight of statistical validity, methodology framing, and novelty claims. The 50% time-saving threshold is not reliably met for the full task.
Task automatabilityclaude-sonnet-53/5AI can draft sections, help format citations, and generate presentation slides, but synthesizing biostatistical findings into a coherent, accurate scientific narrative requires domain judgment and verification that current tools cannot fully replace.
Adoption barriersclaude-haiku-4-5-202510014/5Professional liability and accountability for statistical claims in peer-reviewed publications create strong barriers: the biostatistician must personally stand behind analytical claims, and editors/reviewers expect human expertise evident in the manuscript. Regulatory and professional norms strongly discourage fully automated article generation.
Adoption barriersclaude-sonnet-53/5No licensing requirement for writing itself, but journal norms, authorship accountability, and scientific integrity standards require named human authors to vouch for content and methodology.
Cost vs. human wageclaude-haiku-4-5-202510012/5Current AI writing tools (ChatGPT, Copilot) are inexpensive per use, but require significant biostatistician time for validation, rewriting, and fact-checking, making all-in cost comparable to or higher than writing from scratch for specialized content.
Cost vs. human wageclaude-sonnet-53/5AI writing assistance is cheap per query, but the human oversight, statistical verification, and revision cycles needed keep total cost roughly comparable to a biostatistician's own drafting time for a rigorous publication.
Technical feasibility todayclaude-haiku-4-5-202510012/5While writing assistants and grammar tools exist, no deployed product reliably handles the domain-specific scientific article production task that biostatisticians face, which requires accurate statistical interpretation and methodological rigor. Existing tools operate at the language level, not the statistical-integrity level required here.
Technical feasibility todayclaude-sonnet-53/5Deployed tools like ChatGPT, Grammarly, and reference managers with AI assist writing and formatting, but no product reliably produces publication-ready biostatistics articles without heavy human editing and fact-checking.

Draw conclusions or make predictions, based on data summaries or statistical analyses.

35

CI 25–45 · exposure 38 · augmentation 75 · importance 4.5/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Biostatistics is embedded in regulated pharmaceutical and clinical research environments with high friction to automation; while tech companies and large biotech firms experiment with AI-assisted analytics, production deployment of autonomous conclusion-drawing remains rare. Adoption is slower than in unregulated data science.
Sector adoption velocityclaude-sonnet-53/5Pharma and biotech are increasingly adopting AI-assisted analytics and reporting tools, but production use for autonomous conclusion-drawing remains limited and cautious given regulatory stakes.
Augmentation potentialclaude-haiku-4-5-202510014/5AI assistants significantly augment biostatistician productivity by automating routine analyses, generating summary tables, surfacing patterns, and proposing hypotheses—keeping the human in the loop for interpretation and validation. This assistive role is already being adopted and visibly raises productivity.
Augmentation potentialclaude-sonnet-54/5AI substantially aids biostatisticians by drafting narrative summaries, flagging patterns, and suggesting hypotheses, meaningfully boosting productivity while the human retains final interpretive judgment.
Task automatabilityclaude-haiku-4-5-202510013/5AI systems can perform statistical analyses and generate preliminary predictions from data summaries, but drawing defensible scientific conclusions requires domain expertise, causal reasoning, and contextual judgment that AI cannot reliably do end-to-end without human validation. Roughly half the workflow (data preparation, analysis runs, pattern identification) can be automated, but interpretation and conclusion-drawing remain human-dependent.
Task automatabilityclaude-sonnet-52/5Drawing valid scientific conclusions requires deep domain judgment, understanding of study design flaws, and biological plausibility assessment that current AI cannot reliably replicate end-to-end, though it can assist with pattern description.5 It can generate plausible-sounding but sometimes unfounded or context-blind conclusions, limiting unsupervised automation.
Adoption barriersclaude-haiku-4-5-202510014/5Regulatory oversight (FDA, EMA, clinical trial guidance) typically requires a qualified statistical expert to sign off on conclusions and analyses in regulated contexts; institutional review boards and data governance policies further mandate human statistical review. These create substantial legal and professional liability barriers to full automation.
Adoption barriersclaude-sonnet-54/5In regulated contexts (clinical trials, FDA submissions), conclusions must be validated and signed off by credentialed biostatisticians/scientists, creating strong liability and regulatory barriers to pure automation.
Cost vs. human wageclaude-haiku-4-5-202510012/5AI can reduce the cost of routine analysis runs and summarization, but biostatistician review, iteration, and expertise remain necessary, limiting overall savings. The all-in cost of AI plus mandatory human oversight remains comparable to or slightly less than a biostatistician's loaded wage.
Cost vs. human wageclaude-sonnet-53/5AI can cheaply generate draft interpretations, but the necessary human verification, domain expertise, and regulatory review largely offset savings, making costs roughly comparable once oversight is included.
Technical feasibility todayclaude-haiku-4-5-202510013/5Products exist (statistical software with AI/ML modules, LLM-based analytics assistants) that can perform parts of this task, but they produce material error rates in causal inference and often miss domain-specific confounders or assumptions that biostatisticians must catch. No production system today reliably draws sound conclusions independently.
Technical feasibility todayclaude-sonnet-52/5AI tools (e.g., LLM-based data analysis assistants) can summarize statistical outputs but reliable, production-grade autonomous inference-drawing in regulated biostatistics contexts is not deployed at scale today.

Develop or use mathematical models to track changes in biological phenomena, such as the spread of infectious diseases.

34

CI 25–44 · exposure 38 · augmentation 75 · importance 3.5/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Biostatistics operates in regulated sectors (public health, pharma) with slower AI adoption cycles. While modeling software adoption is widespread, autonomous AI-driven model development and deployment remain rare in production; most organizations still rely on human biostatisticians as gatekeepers.
Sector adoption velocityclaude-sonnet-52/5Biostatistics and public health sectors are cautious adopters of AI due to rigorous validation needs, though computational tools are increasingly used for exploratory analysis.
Augmentation potentialclaude-haiku-4-5-202510014/5AI substantially augments biostatistician productivity by automating parameter fitting, running simulations, generating visualizations, and flagging anomalies, allowing experts to focus on interpretation, model critique, and communication. The human remains essential for judgment but works faster and explores more scenarios.
Augmentation potentialclaude-sonnet-54/5AI substantially aids literature synthesis, code generation, parameter estimation, and simulation exploration, meaningfully speeding up the biostatistician's modeling workflow while the human retains final judgment.
Task automatabilityclaude-haiku-4-5-202510013/5AI can automate parts of model development (e.g., parameter estimation, simulation execution) and data processing, but epidemiological modeling often requires domain expertise in model selection, validation against real-world data, and interpretation of results that currently demands human judgment. The task achieves roughly 50% time savings on routine components but falls short on full end-to-end automation.
Task automatabilityclaude-sonnet-52/5AI can help draft or run model code and even suggest model structures, but designing valid epidemiological/biological models requires domain judgment, data curation, and validation that current systems cannot autonomously perform end-to-end at equal quality.
Adoption barriersclaude-haiku-4-5-202510014/5Public health decisions based on disease models carry high error-cost asymmetry and regulatory scrutiny (FDA, CDC oversight); results influence policy affecting millions. A qualified human biostatistician is typically required to validate, interpret, and sign off on models used in official guidance, creating a strong licensing/liability barrier to full automation.
Adoption barriersclaude-sonnet-53/5No licensing requirement mandates a human specifically, but publication, regulatory submissions, and public health decisions relying on these models require accountable expert sign-off, creating moderate friction.
Cost vs. human wageclaude-haiku-4-5-202510012/5While computational inference is cheap, the integration overhead, model development, and required expert validation add significant cost. For many organizations, the all-in cost of AI-assisted modeling still exceeds hiring a biostatistician for routine tasks, especially given liability concerns in public health.
Cost vs. human wageclaude-sonnet-52/5While AI can cut coding and literature-review time, the need for expert validation, data cleaning, and domain-specific calibration keeps overall costs close to human-led efforts.
Technical feasibility todayclaude-haiku-4-5-202510013/5Products exist for specific modeling subtasks—statistical software, simulation libraries, and ML-based forecasting tools—but they operate with material limitations when deployed to novel disease scenarios or complex real-world systems. No single AI product reliably performs the entire workflow (design, calibration, validation, interpretation) in production without substantial human oversight.
Technical feasibility todayclaude-sonnet-52/5Some AI-assisted modeling tools and coding copilots exist, but no deployed product reliably builds and validates disease-spread models without expert oversight in production settings.

Write detailed analysis plans and descriptions of analyses and findings for research protocols or reports.

33

CI 29–37 · exposure 33 · augmentation 75 · importance 4.4/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Biostatistics remains a specialized, human-centric field with slower AI adoption due to regulatory constraints and the high cost of analytical errors. Adoption is limited to assistive use in information-rich organizations, not displacement.
Sector adoption velocityclaude-sonnet-52/5Biostatistics and clinical research organizations tend to be cautious adopters of generative AI due to regulatory sensitivity, validation requirements, and data privacy concerns, so uptake for actual document authorship is currently limited to pilots.
Augmentation potentialclaude-haiku-4-5-202510014/5AI assists biostatisticians by drafting outlines, generating standard language, suggesting statistical approaches, and summarizing findings, meaningfully accelerating document production while the expert retains judgment and control. This augmentative use is already common in practice.
Augmentation potentialclaude-sonnet-54/5AI tools are already useful for drafting boilerplate sections, summarizing prior analyses, generating text templates, and checking language/consistency, meaningfully speeding up the biostatistician's writing process while they retain final control.
Task automatabilityclaude-haiku-4-5-202510012/5While AI can generate template outlines and draft portions of analysis plans, the task requires deep scientific judgment about study design, statistical appropriateness, and context-specific methodological choices that current systems struggle with consistently. Producing a complete, publishable analysis plan requires domain expertise and human oversight that prevents the 50% time-saving threshold from being reliably met.
Task automatabilityclaude-sonnet-53/5LLMs can draft substantial portions of a statistical analysis plan (SAP) template based on protocol details, but the core requires domain-specific judgment about design, endpoints, and regulatory compliance that still needs expert authorship and validation.rating captures partial but not full automation.
Adoption barriersclaude-haiku-4-5-202510014/5Regulatory bodies (FDA, EMA) and journals require explicit human sign-off on statistical analysis plans and methodology; liability for statistical errors rests with the credentialed biostatistician, not an automated system. These legal and institutional barriers meaningfully restrict autonomous deployment.
Adoption barriersclaude-sonnet-54/5SAPs for clinical/regulatory research often require sign-off by qualified biostatisticians and are subject to regulatory review (e.g., FDA, IRB), creating strong barriers to full automation and accountability requirements for a credentialed human.
Cost vs. human wageclaude-haiku-4-5-202510013/5AI inference cost is low, but integration overhead, validation, and human correction time bring total cost closer to parity with junior biostatistician wages. The need for expert human review of generated content limits the cost advantage.
Cost vs. human wageclaude-sonnet-53/5AI drafting reduces time spent on boilerplate sections, but the necessary expert review, validation against protocol specifics, and regulatory scrutiny keep overall costs roughly comparable to fully human-authored plans in regulated contexts.
Technical feasibility todayclaude-haiku-4-5-202510012/5No mature product reliably generates end-to-end, publication-ready analysis plans; biostatisticians use AI tools for drafting and suggestions only, not autonomous production. Current systems lack the domain-specific knowledge and error-checking required for regulatory or peer-review standards in biostatistics.
Technical feasibility todayclaude-sonnet-52/5AI writing tools can generate boilerplate text and structure for SAPs but no deployed product reliably produces regulatory-grade, statistically sound analysis plans without heavy biostatistician revision; this remains largely a drafting aid rather than a finished-product solution.

Assign work to biostatistical assistants or programmers.

28

CI 25–30 · exposure 25 · augmentation 50 · importance 3.5/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Biostatistics organizations are moderately digitized but task assignment remains embedded in managerial judgment and team relationships; adoption of AI-driven delegation is not evident in production settings to date.
Sector adoption velocityclaude-sonnet-52/5Biostatistics and pharma/clinical research sectors are moderate adopters of AI for data tasks, but managerial delegation functions remain largely untouched by AI tools.
Augmentation potentialclaude-haiku-4-5-202510013/5AI could assist by suggesting candidate tasks for the biostatistician, flagging skill gaps, or summarizing workload—useful productivity aids—but the human retains decision authority and final assignment responsibility.
Augmentation potentialclaude-sonnet-53/5AI can help track workloads, suggest task allocations based on skills/capacity data, and draft communications, aiding managers without replacing their judgment.
Task automatabilityclaude-haiku-4-5-202510012/5Assigning work requires understanding task complexity, team capability, deadlines, and dependencies—contextual judgment that current AI systems cannot reliably perform end-to-end. While AI could draft assignment recommendations, a human biostatistician must validate feasibility and adjust for team dynamics, leaving at most 20–30% time savings.
Task automatabilityclaude-sonnet-52/5Assigning work requires judgment about staff skills, project priorities, and interpersonal dynamics that current AI cannot reliably assess or execute end-to-end.ithm.
Adoption barriersclaude-haiku-4-5-202510014/5Organizational hierarchy and accountability norms require a qualified biostatistician to assign and take responsibility for delegated work; regulatory and institutional friction against automated delegation of oversight responsibilities creates meaningful barriers to substitution.
Adoption barriersclaude-sonnet-53/5No explicit licensing requirement for task assignment, but organizational hierarchy, accountability for errors, and trust in managerial judgment create real friction against full automation.
Cost vs. human wageclaude-haiku-4-5-202510012/5Overhead of integration, prompt engineering, review, and corrections by the assigning biostatistician likely approaches or exceeds the small time saving, making AI cost-comparable or higher than direct human assignment.
Cost vs. human wageclaude-sonnet-52/5Human managers still need to perform this task; AI scheduling aids provide minor efficiency but don't replace the managerial cost of decision-making and accountability.
Technical feasibility todayclaude-haiku-4-5-202510012/5No deployed product reliably performs biostatistical task assignment in production. General workflow management and PM tools exist but do not understand biostatistical task scope or personnel skill mapping with the accuracy required for real-world deployment.
Technical feasibility todayclaude-sonnet-52/5No deployed product autonomously assigns work to biostatistical staff; project management tools assist scheduling but don't make substantive delegation decisions.

Design surveys to assess health issues.

28

CI 25–30 · exposure 25 · augmentation 75 · importance 3.3/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Health and biostatistics sectors maintain conservative, regulation-bound practices; while some institutions experiment with AI drafting tools, meaningful production adoption of AI-driven survey design remains limited, with most organizations still relying on traditional expert-led design.
Sector adoption velocityclaude-sonnet-52/5Health research and biostatistics is a professional services-adjacent field with growing AI pilot use, but adoption for core methodological design tasks remains slow and cautious due to scientific rigor requirements.
Augmentation potentialclaude-haiku-4-5-202510014/5AI can meaningfully augment survey design by generating question pools, checking for bias or redundancy, suggesting sampling strategies, and automating preliminary statistical calculations, allowing biostatisticians to focus on validation and clinical interpretation rather than rote drafting.
Augmentation potentialclaude-sonnet-54/5AI tools can meaningfully assist with literature review, question wording, drafting instruments, and identifying potential biases, significantly speeding up the ideation and drafting phases.
Task automatabilityclaude-haiku-4-5-202510012/5AI can assist with survey template generation and statistical design recommendations, but designing clinically valid, ethically sound health surveys requires domain expertise, stakeholder input, and judgment about which health issues to prioritize—tasks that remain substantially human-driven and not amenable to 50% time savings end-to-end.
Task automatabilityclaude-sonnet-52/5Survey design requires domain judgment about population, bias, sampling frame, and validity that current AI can assist with but not fully replace end-to-end at equal quality without expert oversight.rationale
Adoption barriersclaude-haiku-4-5-202510014/5Health survey design is regulated under IRB/ethics review frameworks and often requires licensed or credentialed professionals to sign off on methodology; liability for flawed study design falls heavily on the organization and principal investigator, creating strong legal and governance barriers to full automation.
Adoption barriersclaude-sonnet-53/5No strict licensing requirement for survey design itself, but institutional review boards, methodological rigor standards, and organizational trust in credentialed biostatisticians create moderate friction.
Cost vs. human wageclaude-haiku-4-5-202510012/5AI-assisted survey drafting reduces marginal labor, but the full cost of design (validation, expert review, regulatory alignment, stakeholder consultation) remains substantial relative to the time savings, making the all-in cost ratio unfavorable compared to hiring a biostatistician.
Cost vs. human wageclaude-sonnet-52/5While AI drafting is cheap, the need for expert biostatistical review and validation to avoid costly methodological errors keeps overall cost comparable to human-led design.
Technical feasibility todayclaude-haiku-4-5-202510012/5While AI can draft survey questions and suggest sampling strategies via prompting or specialized tools, no deployed product reliably designs complete health surveys from specification to validation; real-world survey design involves iterative testing, regulatory review, and adaptation that current systems handle only partially.
Technical feasibility todayclaude-sonnet-52/5No deployed product autonomously designs valid health surveys; existing tools (e.g., chatbots, survey platforms with AI suggestions) provide drafting help but require substantial expert revision.

Analyze clinical or survey data, using statistical approaches such as longitudinal analysis, mixed-effect modeling, logistic regression analyses, and model-building techniques.

26

CI 25–28 · exposure 25 · augmentation 75 · importance 4.4/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Biostatisticians work in regulated pharma, healthcare, and academic research environments with slow digitization of analytical workflows and entrenched oversight processes. Adoption of AI automation is cautious and limited mainly to code-generation assistance rather than end-to-end replacement.
Sector adoption velocityclaude-sonnet-53/5Pharma and clinical research sectors are increasingly adopting AI-assisted coding and analysis tools, but adoption is tempered by regulatory caution and validation requirements, placing it in the middle range.
Augmentation potentialclaude-haiku-4-5-202510014/5AI systems can meaningfully augment biostatisticians by automating routine coding, suggesting model structures, generating diagnostic plots, and accelerating computation, allowing experts to focus on interpretation, validation, and clinical translation. This assistive role is already valuable in practice.
Augmentation potentialclaude-sonnet-54/5AI coding assistants and statistical copilots meaningfully speed up code generation, exploratory analysis, and documentation, significantly boosting biostatistician productivity while they retain responsibility for model choice and validation.
Task automatabilityclaude-haiku-4-5-202510012/5While AI can assist with statistical computations and suggest model structures, the task requires domain expertise to select appropriate statistical approaches, interpret clinical context, and make judgments about data quality and model validity that current systems cannot reliably do end-to-end. The human must still direct the overall analytical strategy.
Task automatabilityclaude-sonnet-52/5AI can execute standard statistical models and generate code, but selecting appropriate methods, validating assumptions, handling messy clinical data, and interpreting results in a regulatory context still require substantial expert judgment that current tools cannot fully replace end-to-end.
Adoption barriersclaude-haiku-4-5-202510014/5Clinical data analysis is heavily regulated (FDA guidance, CDISC standards, IRB oversight) and often requires a licensed biostatistician to sign statistical analysis plans and validate results. Liability for erroneous inferences in drug trials or clinical decisions creates strong legal and organizational friction against full automation.
Adoption barriersclaude-sonnet-54/5Clinical trial statistics often require sign-off by credentialed biostatisticians for regulatory submissions (FDA, EMA), creating strong liability and compliance barriers to full automation.
Cost vs. human wageclaude-haiku-4-5-202510012/5AI tools for statistical analysis (code generation, model fitting) reduce some computational overhead, but the skilled biostatistician's expertise in design and interpretation remains essential; the all-in cost of AI plus human oversight often approaches or exceeds the cost of direct expert analysis.
Cost vs. human wageclaude-sonnet-52/5While AI can cheaply generate code and summaries, the need for expert statistician review, validation against regulatory standards (e.g., FDA submissions), and error correction keeps effective cost savings modest compared to a fully human-driven workflow.
Technical feasibility todayclaude-haiku-4-5-202510012/5Statistical software and some AI-assisted code generation tools exist, but no deployed product reliably performs the full analytical workflow—from data understanding through model selection, validation, and clinical interpretation—without significant human oversight and correction. Current systems lack the contextual reasoning required for clinical data analysis.
Technical feasibility todayclaude-sonnet-52/5Products like Copilot-assisted R/SAS/Python workflows and AI coding assistants can run models, but no deployed product autonomously performs full biostatistical analysis for clinical trials reliably at production scale without expert oversight.

Review clinical or other medical research protocols and recommend appropriate statistical analyses.

26

CI 25–28 · exposure 25 · augmentation 75 · importance 4.2/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Biostatistics remains a specialized field with strong professional gatekeeping and regulatory oversight; adoption of AI for autonomous protocol review is minimal, with AI primarily used as a supplementary tool rather than a replacement.
Sector adoption velocityclaude-sonnet-53/5Pharma and clinical research sectors are increasingly piloting AI for protocol review and statistical planning, but production-grade autonomous use remains limited due to regulatory caution.
Augmentation potentialclaude-haiku-4-5-202510014/5AI can meaningfully assist biostatisticians by rapidly generating candidate statistical approaches, reviewing literature suggestions, and flagging common design issues, allowing the expert to focus on judgment and contextual evaluation rather than initial synthesis.
Augmentation potentialclaude-sonnet-54/5AI tools can meaningfully speed up literature review, draft statistical analysis plans, and flag methodological issues, significantly aiding biostatisticians while they retain final judgment.
Task automatabilityclaude-haiku-4-5-202510012/5While AI can assist in suggesting standard statistical approaches for common experimental designs, reviewing protocols requires deep domain knowledge of medical context, regulatory requirements, and nuanced judgment about appropriateness—tasks at which current AI systems perform poorly and inconsistently at scale.
Task automatabilityclaude-sonnet-52/5AI can draft or critique statistical sections but designing appropriate analyses for novel trial designs requires domain judgment, regulatory awareness, and accountability that current systems cannot reliably replace end-to-end.
Adoption barriersclaude-haiku-4-5-202510014/5Regulatory frameworks (FDA, ICH) and institutional review boards often require a qualified biostatistician to formally approve statistical approaches; liability for inappropriate analyses falls on the responsible human, creating a strong legal barrier to full automation.
Adoption barriersclaude-sonnet-54/5Clinical trial statistical plans typically require sign-off by qualified biostatisticians for regulatory submission (e.g., FDA, IRB requirements), creating strong professional and legal barriers to full automation.
Cost vs. human wageclaude-haiku-4-5-202510012/5Current AI systems require substantial expert oversight to validate their recommendations, making the all-in cost (inference, integration, human review) comparable to or potentially higher than direct biostatistician review.
Cost vs. human wageclaude-sonnet-52/5AI assistance is cheap per query, but the human oversight, validation against regulatory standards, and liability review needed keep effective cost comparable to or only modestly below a biostatistician's time.
Technical feasibility todayclaude-haiku-4-5-202510012/5No deployed product reliably recommends appropriate statistical analyses for novel or complex medical protocols without significant expert review and correction; existing tools offer templates and suggestions but cannot replace human biostatistician judgment in production medical research environments.
Technical feasibility todayclaude-sonnet-52/5LLM-based tools can suggest statistical approaches or flag issues in protocols, but no deployed product independently reviews and certifies protocol statistical plans in production biostatistics workflows.

Provide biostatistical consultation to clients or colleagues.

25

CI 25–25 · exposure 25 · augmentation 75 · importance 4.3/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Biostatistics is concentrated in regulated sectors (pharma, clinical research, healthcare) that move cautiously on automation due to compliance requirements; adoption remains limited to augmentation (e.g., drafting statistical code) rather than autonomous consultation.
Sector adoption velocityclaude-sonnet-52/5Biostatistics and clinical research sectors have been cautious in adopting AI for core statistical judgment tasks, with adoption concentrated in drafting/support tools rather than replacing consultation itself.
Augmentation potentialclaude-haiku-4-5-202510014/5AI can meaningfully assist biostatisticians by drafting analysis plans, suggesting appropriate methods, generating boilerplate statistical code, and flagging potential confounders, thereby freeing experts to focus on judgment-heavy aspects of study design and client communication.
Augmentation potentialclaude-sonnet-54/5AI can meaningfully assist by drafting methodology explanations, running exploratory analyses, summarizing literature, and generating code, boosting biostatistician productivity while they retain final judgment.
Task automatabilityclaude-haiku-4-5-202510012/5Biostatistical consultation requires understanding nuanced experimental design, context-specific assumptions, and client goals—tasks where AI can draft proposals or flag methodological issues but cannot reliably replace the iterative, judgment-driven dialogue that defines consultation. Current systems lack the domain depth and interactive reasoning to independently advise on study validity.
Task automatabilityclaude-sonnet-52/5Consultation requires interpreting nuanced study goals, negotiating tradeoffs, and building trust in real time, which current AI cannot fully replicate; only narrow sub-parts like generating draft statistical explanations can be automated.
Adoption barriersclaude-haiku-4-5-202510014/5Regulatory frameworks (FDA, EMA guidance on clinical trial design) often require a qualified biostatistician to sign off on analysis plans; professional liability and the high cost of statistical errors in regulated settings create strong disincentives to full automation without human accountability.
Adoption barriersclaude-sonnet-54/5Consultations often feed into regulatory submissions, clinical trial design, and publications, requiring accountable expert sign-off, creating strong professional and liability barriers.
Cost vs. human wageclaude-haiku-4-5-202510012/5AI-powered consultation tools are emerging but still require expert oversight and integration into workflows; the all-in cost (model, integration, expert review) remains comparable to or exceeds the cost of junior biostatisticians handling routine consultations.
Cost vs. human wageclaude-sonnet-52/5While drafting help is cheap, real consultation demands validated judgment and liability coverage a human expert provides; AI cost savings are offset by need for verification and correction by a qualified biostatistician.
Technical feasibility todayclaude-haiku-4-5-202510012/5While LLMs can retrieve statistical references and suggest methods, no deployed product reliably performs independent biostatistical consultation at production quality; organizations still require human biostatisticians to validate AI suggestions and engage directly with clients on study design assumptions and risk.
Technical feasibility todayclaude-sonnet-52/5AI tools (chatbots, statistical assistants) can support answering methodological questions, but no deployed product independently provides reliable biostatistical consultation in real clinical/research settings without expert oversight.

Determine project plans, timelines, or technical objectives for statistical aspects of biological research studies.

25

CI 25–25 · exposure 25 · augmentation 63 · importance 4.2/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Biostatistics remains a human-expert-dependent field with slower adoption of AI automation; planning and objective-setting are particularly resistant to substitution because they are early-stage, high-stakes decisions that organizations prefer to keep under expert human control.
Sector adoption velocityclaude-sonnet-52/5Biopharma and academic research organizations are cautious adopters of AI for core statistical planning due to regulatory scrutiny and validation requirements, with pilots more common than production use.
Augmentation potentialclaude-haiku-4-5-202510013/5AI can meaningfully assist by suggesting statistical frameworks, generating timeline templates, or flagging common pitfalls, helping a biostatistician work faster, but the core task of determining objectives still requires human expertise and judgment.
Augmentation potentialclaude-sonnet-54/5AI can meaningfully assist by drafting timelines, summarizing precedent study designs, and suggesting statistical approaches, boosting biostatistician productivity while they retain final judgment.
Task automatabilityclaude-haiku-4-5-202510012/5AI can assist with generating template timelines and identifying standard statistical milestones, but determining project plans and technical objectives requires deep domain knowledge of the specific research hypotheses, biological constraints, regulatory requirements, and resource availability that typically demand human biostatistician judgment.
Task automatabilityclaude-sonnet-52/5This requires domain judgment about study design, regulatory context, and stakeholder alignment that current AI cannot reliably synthesize end-to-end; AI can draft components but not own the planning decision.
Adoption barriersclaude-haiku-4-5-202510014/5Regulatory compliance (FDA, IRB requirements), institutional liability for study design flaws, and the requirement that a qualified biostatistician must approve and sign off on statistical objectives create strong legal and organizational barriers to full automation.
Adoption barriersclaude-sonnet-54/5Clinical and biological research often falls under regulatory frameworks (FDA, IRB, GxP) requiring qualified professional sign-off on study design and statistical plans, creating strong liability and compliance barriers.
Cost vs. human wageclaude-haiku-4-5-202510012/5Current AI tools (LLMs, planning assistants) are relatively inexpensive for generating draft plans, but the integration, validation, and human oversight needed to produce a usable project plan approaches or exceeds the loaded cost of a biostatistician's time spent on this task.
Cost vs. human wageclaude-sonnet-52/5Given the need for expert oversight, regulatory awareness, and iterative stakeholder negotiation, AI assistance reduces some drafting time but doesn't yet cut overall cost dramatically versus a trained biostatistician.
Technical feasibility todayclaude-haiku-4-5-202510012/5No deployed product reliably performs end-to-end project planning and objective-setting for biostatistical studies in production. AI tools can draft outline plans or suggest statistical approaches, but real-world planning requires integrating domain expertise, stakeholder input, and iterative refinement that exceeds current system capability.
Technical feasibility todayclaude-sonnet-52/5No deployed product autonomously sets project plans or technical objectives for biostatistics studies; existing tools support drafting timelines or protocols but require heavy human direction and validation.

Collect data through surveys or experimentation.

25

CI 25–25 · exposure 25 · augmentation 63 · importance 3.6/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Biostatistics is a regulated, slow-moving sector embedded in pharmaceutical, healthcare, and academic research. While online survey tools have been adopted, the core experimental design and validation step remains human-driven due to regulatory and quality requirements; AI agent adoption in this function is nascent.
Sector adoption velocityclaude-sonnet-52/5Biostatistics and clinical research sectors are cautious adopters of AI for data collection due to regulatory and ethical constraints, with adoption mostly limited to pilot digital data capture tools rather than widespread autonomous systems.
Augmentation potentialclaude-haiku-4-5-202510013/5AI can assist biostatisticians by generating survey templates, identifying potential sources of bias, automating data cleaning and entry, and suggesting experimental designs for review. These are useful productivity aids, but the human remains the decision-maker on design validity and statistical soundness.
Augmentation potentialclaude-sonnet-54/5AI tools significantly aid in designing survey instruments, automating data entry, flagging anomalies, and streamlining logistics, meaningfully boosting productivity while humans remain responsible for oversight and ethical compliance.
Task automatabilityclaude-haiku-4-5-202510012/5Survey design and distribution can be partially automated (questionnaire generation, data collection via online platforms), but the core design of experiment protocols—selecting variables, determining sample size, avoiding bias—requires domain expertise and human judgment. Current AI cannot autonomously perform valid experimental design end-to-end at the quality required in biostatistics.
Task automatabilityclaude-sonnet-52/5Data collection via surveys or experiments requires designing instruments, recruiting subjects, physical or logistical setup, and ensuring protocol compliance, which AI cannot fully execute autonomously today. AI can assist with survey design and distribution logistics but not the end-to-end collection process, especially for experiments requiring physical presence or biological samples.
Adoption barriersclaude-haiku-4-5-202510014/5Institutional Review Boards (IRBs), regulatory oversight (FDA, HIPAA), and professional liability require a human biostatistician to take responsibility for study design, protocol compliance, and data integrity. These are hard legal and compliance barriers that prevent full automation.
Adoption barriersclaude-sonnet-54/5Clinical and experimental data collection is often subject to IRB approval, regulatory compliance (e.g., FDA, HIPAA), and requires qualified personnel to ensure ethical and procedural standards, creating strong barriers to full automation.
Cost vs. human wageclaude-haiku-4-5-202510012/5Online survey platforms and basic data collection systems are cheap, but the labor cost of a biostatistician designing and overseeing data collection remains high. AI reduces friction in routine data entry and logistics, but the specialized intellectual work cannot be significantly displaced, keeping the ratio unfavorable.
Cost vs. human wageclaude-sonnet-52/5While software tools reduce marginal cost for digital surveys, biostatistics often involves clinical or experimental data collection requiring human oversight, recruitment, and compliance, keeping AI-driven cost savings modest relative to human labor.
Technical feasibility todayclaude-haiku-4-5-202510012/5Automated survey tools and data collection platforms exist and are widely used, but these are infrastructure, not AI autonomy. LLMs cannot independently design statistically sound experiments or surveys; they can assist with template generation but cannot replace the experimental design and validation step that biostatisticians must perform.
Technical feasibility todayclaude-sonnet-52/5Some products exist for online survey deployment and automated data capture (e.g., digital survey platforms with AI-assisted question generation), but no deployed system autonomously runs experiments or ensures rigorous data collection protocols in biostatistics contexts.

Apply research or simulation results to extend biological theory or recommend new research projects.

21

CI 11–30 · exposure 13 · augmentation 63 · importance 3.6/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510012/5Biostatistics operates in academic and regulated pharmaceutical contexts with slow AI adoption for core scientific tasks. While institutions adopt AI for data management and analysis support, the theoretical and research-direction components remain human-led; adoption of AI for these roles is nascent and cautious.
Sector adoption velocityclaude-sonnet-52/5Biostatistics and academic/pharma research sectors are adopting AI tools for data analysis and literature review, but using AI to autonomously extend theory or set research agendas remains rare and experimental.
Augmentation potentialclaude-haiku-4-5-202510013/5AI can usefully assist biostatisticians by synthesizing literature, visualizing simulation results, and flagging patterns in data, which can inspire theoretical thinking. However, the human biostatistician must perform the actual theoretical extension and research judgment, making AI a secondary analytical aid rather than a transformative productivity tool.
Augmentation potentialclaude-sonnet-54/5AI can meaningfully assist by summarizing literature, identifying patterns in simulation outputs, and brainstorming hypotheses, substantially aiding a biostatistician's exploratory and theoretical work while they retain final judgment.
Task automatabilityclaude-haiku-4-5-202510012/5This task requires integrating research findings with deep theoretical knowledge and formulating novel research directions—activities that demand significant human judgment, domain expertise, and creative synthesis. Current AI can assist with literature synthesis and simulation analysis, but cannot independently determine theoretical extensions or credibly recommend new research directions at the quality expected in biostatistics.
Task automatabilityclaude-sonnet-51/5This requires deep scientific judgment, creativity, and domain expertise to interpret simulation/research results and extend theory or propose novel research directions—AI cannot reliably perform this end-to-end today.
Adoption barriersclaude-haiku-4-5-202510014/5Institutional research governance, peer review expectations, and scientific credibility norms create strong barriers: novel theoretical extensions must be authored and defended by credentialed researchers, and funding agencies typically require human PI sign-off on research direction. Liability for poor research recommendations also rests with the responsible scientist.
Adoption barriersclaude-sonnet-53/5No licensing requirement specifically bars AI from suggesting research directions, but scientific credibility, peer review norms, and institutional trust in human-authored theoretical contributions create substantial organizational friction.
Cost vs. human wageclaude-haiku-4-5-202510012/5The cost of AI tools (LLMs, analysis platforms) plus required oversight by experienced biostatisticians to validate recommendations exceeds the direct cost of having a biostatistician perform the task independently, given the high error cost of invalid theoretical claims or poor research direction.
Cost vs. human wageclaude-sonnet-52/5While AI inference is cheap, the output requires extensive expert verification and correction, so the effective cost of usable, trustworthy scientific insight is not dramatically cheaper than a skilled biostatistician's time.
Technical feasibility todayclaude-haiku-4-5-202510012/5While AI systems can analyze simulation results and summarize research, no deployed product reliably performs end-to-end theoretical extension or research recommendation in biostatistics without substantial human oversight and domain expertise. Attempts would require human biostatisticians to validate and substantially revise AI suggestions.
Technical feasibility todayclaude-sonnet-51/5No deployed product autonomously extends biological theory or generates validated novel research recommendations; this remains firmly in the research/exploratory stage even for advanced LLMs.

Teach graduate or continuing education courses or seminars in biostatistics.

19

CI 14–25 · exposure 20 · augmentation 63 · importance 3.3/5 · click for rater detail

Panel ratings per dimension for this task
DimensionModelRatingRationale
Sector adoption velocityclaude-haiku-4-5-202510011/5Academic institutions are laggards in automating core teaching roles; graduate education depends on mentorship and live interaction, with no measurable production deployment of AI-only instructors in biostatistics or similar fields.
Sector adoption velocityclaude-sonnet-52/5Higher education adopts AI slowly for core instructional delivery, though usage of AI-assisted content creation is growing; institutional and accreditation inertia is significant.
Augmentation potentialclaude-haiku-4-5-202510013/5AI can assist instructors by generating initial drafts of lecture content, creating homework problems, providing students with tutoring assistance, and helping grade assignments—moderately boosting instructor productivity without replacing the instructor.
Augmentation potentialclaude-sonnet-54/5AI substantially aids in generating slides, practice problems, quizzes, explanations, and adaptive materials, meaningfully increasing instructor efficiency.
Task automatabilityclaude-haiku-4-5-202510012/5AI can generate lecture notes, slides, and problem sets at scale, but teaching involves real-time interaction, student assessment, adaptive questioning, and the ability to read the room—capabilities current systems lack. Only the preparation phase (maybe 20–30% of teaching work) can be meaningfully automated.
Task automatabilityclaude-sonnet-52/5AI can generate lecture content and slides but cannot conduct live teaching, mentor students, or adapt in real time with the pedagogical judgment expected of a course instructor.'
Adoption barriersclaude-haiku-4-5-202510014/5Universities have accreditation, faculty governance, and institutional expectations that instruction be delivered by credentialed faculty; academic freedom and shared governance create strong organizational and regulatory friction against wholesale replacement of instructors with automated systems.
Adoption barriersclaude-sonnet-54/5Accredited teaching typically requires a credentialed instructor of record, institutional accreditation standards, and human accountability for grading and academic integrity.
Cost vs. human wageclaude-haiku-4-5-202510011/5A biostatistics PhD instructor costs $80–150k loaded annually; producing equivalent pedagogical outcomes (live teaching, mentorship, assessment, curriculum iteration) via AI would require expensive human oversight, custom training, and likely human instruction anyway.
Cost vs. human wageclaude-sonnet-52/5Content-generation costs are low, but the instructor role still requires substantial human oversight, live delivery, and assessment, keeping overall cost comparable to human labor.
Technical feasibility todayclaude-haiku-4-5-202510011/5No deployed product reliably teaches graduate biostatistics courses end-to-end; ChatGPT and similar tools can draft materials but cannot conduct live instruction, manage classroom dynamics, or provide personalized feedback at the depth and nuance required for rigorous graduate education.
Technical feasibility todayclaude-sonnet-52/5AI tools like chatbots and content generators assist in course prep but no deployed product autonomously teaches accredited graduate courses in production today.

Related occupations — Computer & Mathematical

How to read this

A high substitution score does not mean this job disappears — it means a large share of its current tasks face replacement pressure, so the mix of tasks is likely to change. High augmentation alongside substitution typically means the occupation reorganizes around the protected tasks. Wide confidence intervals mean the rater panel disagreed: treat those scores as open questions, not verdicts.

What would change this score

New model capabilities (automatability, feasibility), falling inference costs (cost ratio), regulation and licensing shifts (barriers), and measured sector adoption (velocity) all re-enter at every index release. Each release is recomputed, versioned and kept queryable — scores are claims with a date on them, not permanent labels.